Overview

Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

Status:
Recruiting

Trial end date:
2022-10-01

Target enrollment:
0

Participant gender:
All

Summary

Few previous studies focused on the neoadjuvant treatments of upper urinary or bladder cancer, especially chemotherapy combined with immunotherapy, however, available data of retrospective studies showed this neoadjuvant treatment model might benefit patients. So This prospective Phase II clinical trial was designed to explore the efficacy of chemotherapy combined with PD-1 inhibitor as neoadjuvant therapy in upper urinary and muscle-invasive bladder urothelial carcinoma, then to improve the rate of complete pathological remission, survival and provide medical evidence.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jianzhong Shou

Collaborator:

Peking University First Hospital

Treatments:

Gemcitabine

Criteria

Inclusion Criteria:

1. bladder cancer of T2-4aN0M0

2. upper tract urinary carcinoma of T1-3N0M0 and high grade

3. ECOG 0-1

4. good organ function

5. no previous chemotherapy or immunotherapy

6. Informed consent form signed

Exclusion Criteria:

1. unable to receive chemotherapy or surgery due to physical abnormalities

2. previous cancer history

3. active tuberculosis

4. HIV

5. autoimmune disease

6. anticipating other clinical studies